Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

SLS vs VIVS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SLS Captures Overall Composite Edge (39.3 SELL vs 36.8 SELL), While VIVS Leads 3–2 on Growth & Valuation Pillars

SLS Overall Winner 6-Pillar Tally: SLS 2 – 3 VIVS (1 Tie) Matrix Metrics: SLS 5 – 2 VIVS

As of Nov 19, 2026, SELLAS Life Sciences Group, Inc. (SLS) captures the overall head-to-head institutional edge over VivoSim Labs, Inc. (VIVS) on higher Unified Composite conviction (39.3/100 SELL vs. 36.8/100 SELL) after splitting the core matrix 5–2 (led by Profitability & Quality, Options & Positioning), while VIVS wins 3–2 across the 6-pillar growth and valuation breakdown. SLS trades at $14.86 (N/M Forward P/E, 0.0% operating margin) versus VIVS at $0.29 (N/M Forward P/E, -10117.0% operating margin).

  • Growth vs. Quality Trade-Off: SLS earns the overall head-to-head edge with a stronger Unified Composite Score (39.3/100 SELL vs. VIVS 36.8/100 SELL) and 1.84β · 551% Vol risk profile, whereas VIVS leads top-line expansion (-51.4% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although SLS compares more favorably head-to-head, both SLS (39.3/100 SELL) and VIVS (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: SLS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 60.2); meanwhile VIVS is in a Breakdown options structure phase (RSI 75.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SLS vs VIVS
SLS NASDAQ Head-to-Head Winner
SELLAS Life Sciences Group, Inc. Common Stock
Pharmaceutical Preparations
$14.86
-17.21% 1D
Market Cap $3.7B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.84β · 551% Vol
Unified Composite Score
39.3 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 48.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 60
RSI-14: 60.2 · SMA20: $10.44 · SMA50: $11.11
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
TTM Revenue $112,000
Forward P/E N/M
Beta / 30D Vol 0.83β · 480% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 5.0 Fund 38.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 75
RSI-14: 75.1 · SMA20: $0.15 · SMA50: $0.18

6-Pillar Scorecard Institutional Category Breakdown (SLS 2 – 3 VIVS)

Columns: Metric · SLS · VIVS
1. Valuation Multiples VIVS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 9.6x
2. Growth & Scale VIVS
Revenue Growth (YoY) -82.5% -51.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $112,000
Market Cap $3.7B $2.4M
3. Profitability & Quality SLS
Gross Margin N/A N/A
Operating Margin 0.0% -10117.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -40.3% -343.1%
4. Balance Sheet & Cash Flow VIVS
Cash Generation (TTM) -$28M -$11M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $138M Net Cash $1.4M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SLS
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 176.3% (16th %ile) N/A (N/A)
Put/Call OI Skew 0.43x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SLS (5) vs VIVS (2)
Institutional Metric SLS VIVS Criterion Row Edge
Market Capitalization
Scale
$3.7B $2.4M Larger Scale SLS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-82.5% -51.4% Higher Growth VIVS
Operating Margin (TTM)
Profitability
0.0% -10117.0% Higher Margin SLS
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-40.3% -343.1% Higher ROE SLS
52-Week Range Position
Momentum
57% ($1–$25) 5% ($0–$3) Stronger Trend SLS
Beta / 30D Volatility
Risk Regime
1.84β · 551% Vol 0.83β · 480% Vol Lower Realized Risk VIVS
Unified Institutional Score
Composite Signal
39.3 / 100 (SELL) 36.8 / 100 (SELL) Higher Composite SLS
Trailing 12M Revenue (USD)
Operating Scale
N/A $112,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 9.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$28M ($138M Net Cash) -$11M EBITDA ($1.4M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VIVS +42.28 pp
SLS: +22.41% · VIVS: +64.69%
3M Horizon VIVS +5.8 pp
SLS: -3.88% · VIVS: +1.92%
6M Horizon SLS +174.81 pp
SLS: +96.56% · VIVS: -78.25%
1Y Horizon SLS +921.58 pp
SLS: +834.59% · VIVS: -86.99%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SLS Revenue VIVS Revenue SLS Op. Margin VIVS Op. Margin Margin Leader
FY2019 N/A $0M N/A -882.4% VIVS
FY2020 $0M $0M -893.8% -977.9% SLS
FY2021 $10M N/A -332.8% N/A SLS
FY2022 $0M $0M -4195.0% -765.3% VIVS
FY2023 N/A $0M N/A -4792.2% VIVS
FY2024 N/A $0M N/A -13840.4% VIVS
FY2025 N/A $0M N/A -8761.1% VIVS
FY2026 N/A $0M N/A -8768.7% VIVS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SLS CONSOLIDATION
101d in phase · OBV ACCUMULATION
Current IV 176.3%
IV Percentile 16th %ile
Put/Call OI Skew 0.43x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact SLS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VIVS BREAKDOWN
73d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact VIVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $19.15 · IV 151.5%

SLS Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,915)

Compare $1,915 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 151.5% ATM IV.

5-DAY BULLISH SWING Liq B

Nov 27 $20 / $23 Bull Call Spread

Buy 2x $20C · Sell 2x $23C · 10d

Net Entry $176 Debit
T+5d @ +5% Move +$26 (+15%)
Max Risk / Buffer $176 Capped
5d Edge & Liquidity 0.4x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $17 / $15 Bull Put Spread

Sell 4x $17P · Buy 4x $15P · 59d

Net Entry $340 Credit
Max Credit / Yield +$340 (+73.9% RoM)
Max Risk / Buffer -15.7% Cushion ($460 Mgn)
5d Edge & Liquidity 69% PoP · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SLS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.7B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VIVS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.4M market capitalization and -10117.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SLS vs VIVS Key Questions & Quantitative Answers

As of Nov 19, 2026, SELLAS Life Sciences Group, Inc. (SLS) captures the overall head-to-head institutional edge over VivoSim Labs, Inc. (VIVS) on higher Unified Composite conviction (39.3/100 SELL vs. 36.8/100 SELL) after splitting the core matrix 5–2 (led by Profitability & Quality, Options & Positioning), while VIVS wins 3–2 across the 6-pillar growth and valuation breakdown. SLS trades at $14.86 (N/M Forward P/E, 0.0% operating margin) versus VIVS at $0.29 (N/M Forward P/E, -10117.0% operating margin). Growth vs. Quality Trade-Off: SLS earns the overall head-to-head edge with a stronger Unified Composite Score (39.3/100 SELL vs. VIVS 36.8/100 SELL) and 1.84β · 551% Vol risk profile, whereas VIVS leads top-line expansion (-51.4% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although SLS compares more favorably head-to-head, both SLS (39.3/100 SELL) and VIVS (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: SLS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 60.2); meanwhile VIVS is in a Breakdown options structure phase (RSI 75.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VIVS leads the Growth & Scale pillar: SLS posts -82.5% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VIVS at -51.4% YoY revenue growth and +0.0% YoY earnings growth on $112,000 TTM revenue (N/A gross margin, -10117.0% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), SLS cumulative revenue shifted N/A while VIVS shifted N/A. In operating R&D and SG&A reinvestment, SLS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VIVS.

VIVS screens cheaper on headline valuation multiples. SLS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VIVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SLS (-40.3% ROE) versus VIVS (-343.1% ROE) capital efficiency.

In options market volatility and institutional positioning, SLS carries 176.3% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.43x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.84β · 551% Vol realized risk). By comparison, VIVS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 480% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.